Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE